12/15
10:01 am
caps
Capstone's 2026 Outlook Reaffirms $100M Run-Rate Target and Outlines Path to 10% EBITDA Margins [Yahoo! Finance]
Low
Report
Capstone's 2026 Outlook Reaffirms $100M Run-Rate Target and Outlines Path to 10% EBITDA Margins [Yahoo! Finance]
11/10
07:41 am
caps
Capstone Reaffirms $100 Million 2026 Run-Rate Target with Acquisition Closing by December 15th [Yahoo! Finance]
Medium
Report
Capstone Reaffirms $100 Million 2026 Run-Rate Target with Acquisition Closing by December 15th [Yahoo! Finance]
11/7
01:12 am
caps
Capstone Therapeutics (NASDAQ:CAPS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
High
Report
Capstone Therapeutics (NASDAQ:CAPS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.